Cytokinetics (CYTK) stock price is $63.95, up 2.08% on the day, as of Oct 20, 2026. It has a market cap of $8.46Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap8.46 Bn
P/E-9.46
P/S125.02
Div. Yield0.00
Total Debt (Qtr)275.56 Mn
Revenue Growth (1y) (Qtr)-57.13
Add ratio to table…
About
Cytokinetics Inc is a biopharmaceutical company focused on discovering developing and commercializing novel muscle activators and inhibitors for diseases where muscle performance is compromised. The firm’s scientific foundation lies in the biology of the cytoskeleton and the mechanics of muscle contraction. Its lead product MYQORZO (aficamten) is an oral small molecule inhibitor of cardiac myosin approved for obstructive hypertrophic cardiomyopathy. Beyond MYQORZO the…
Cytokinetics Inc is a biopharmaceutical company focused on discovering developing and commercializing novel muscle activators and inhibitors for diseases where muscle performance is compromised. The firm’s scientific foundation lies in the biology of the cytoskeleton and the mechanics of muscle contraction. Its lead product MYQORZO (aficamten) is an oral small molecule inhibitor of cardiac myosin approved for obstructive hypertrophic cardiomyopathy. Beyond MYQORZO the company advances a pipeline that includes cardiac myosin activators and inhibitors targeting heart failure with reduced ejection fraction heart failure with preserved ejection fraction and neuromuscular disorders. Cytokinetics aims to build a specialty biopharmaceutical business rooted in muscle biology expertise. The company’s long term strategy is to build a sustainable specialty biopharmaceutical business that leverages its deep knowledge of muscle mechanics to address underserved patient populations.
The company generates revenue primarily from product sales of MYQORZO in the United States Europe and China following regulatory approvals in those regions. In addition Cytokinetics earns royalties and milestone payments from licensing agreements with partners such as Sanofi for Greater China and Bayer for Japan. The firm also receives revenue interests tied to future sales of MYQORZO and pipeline candidates through agreements with Royalty Pharma. As its pipeline advances the company anticipates additional income from licensing collaborations milestone achievements and eventual sales of investigational drugs such as omecamtiv mecarbil and ulacamten. Revenue is supplemented by grant funding and collaborative research arrangements that support preclinical and clinical development. The firm also anticipates revenue from potential sales of its investigational candidates pending successful clinical development and regulatory approval.
Cytokinetics occupies a niche within the cardiovascular therapeutics sector as one of few companies concentrating on direct modulation of cardiac myosin to treat hypertrophic cardiomyopathy and heart failure. Its principal rival in the obstructive hypertrophic cardiomyopathy market is Bristol Myers Squibb with Camzyos (mavacamten) while additional competition may arise from Edgewise Therapeutics Lexicon Tenaya and Braveheart Bio. In the heart failure with reduced ejection fraction arena omecamtiv mecarbil could face competition from generic inotropes such as milrinone and dobutamine as well as newer agents like vericiguat and ivabratine. The company’s competitive advantages stem from its deep expertise in muscle cytoskeleton biology a robust patent portfolio covering composition of matter polymorphic forms and formulations of its key molecules and its ability to translate mechanistic insights into oral small molecule therapeutics. Cytokinetics also benefits from a focused commercial model that targets specialized cardiology centers and experienced healthcare professionals. Its dedication to scientific innovation and patient centered care further distinguishes it from larger pharmaceutical competitors.
The company serves patients diagnosed with obstructive hypertrophic cardiomyopathy a condition affecting hundreds of thousands of individuals in the United States and many more worldwide. It also aims to treat patients with non obstructive hypertrophic cardiomyopathy heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. In the neuromuscular arena Cytokinetics is developing therapies for specific forms of muscular dystrophy and other muscle wasting disorders. Healthcare providers such as cardiologists heart failure specialists and neurologists constitute the primary prescribers while hospitals and specialty clinics provide the settings for diagnosis and treatment. Payers including government programs private insurers and managed care organizations determine reimbursement access. The firm has collaborated with Sanofi in China and Bayer in Japan to expand geographic reach and may seek additional distribution partners in other markets. Cytokinetics actively engages with patient advocacy groups to understand unmet needs and to inform its development and commercialization efforts.
Sector:HealthcareSector rationaleCytokinetics is a biopharmaceutical company that discovers, develops, and commercializes medical products, specifically muscle activators and inhibitors like MYQORZO for cardiac diseases. Its revenue is derived from product sales of these drugs, royalties from licensing agreements with partners like Sanofi and Bayer, and milestone payments, all of which fall squarely within the Pharmaceuticals and Biotechnology industries of the Healthcare sector.Industry:PharmaceuticalsPharmaceuticalsPrimaryCytokinetics develops and markets branded prescription drugs, specifically the oral small molecule inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Its revenue is generated from the sales of these branded pharmaceuticals and associated licensing milestones.Classified using BQ-MICSCIK: 0001061983
Bull & bear
Investment Thesis
▲ Bull case
Cytokinetics has established a compelling dual-pathway growth engine through MYCorzo's successful U.S. launch and aficamtin's breakthrough Phase 3 Acacia HCM results, creating immediate revenue momentum and a near-term catalyst for expanded market opportunity. The company achieved $4.8 million in net product revenue from MYCorzo during approximately nine weeks post-launch, exceeding internal expectations for both depth and breadth of prescribing, with over 275 unique HCPs prescribing in Q1 and more than 425 by April, including strong adoption among high-volume prescribers who generate 80% of HCM prescriptions. This early traction is reinforced by over 70% of dispensed patients converting to paid prescriptions within two weeks, indicating sustainable commercial viability beyond free trial programs. Concurrently, aficamtin met both dual primary endpoints in the Acacia HCM trial for nonobstructive HCM, demonstrating a statistically significant and clinically meaningful 3-point least squares mean difference in KCCQ (p=0.021) and 0.67 mL/kg/min improvement in peak VO2 (p=0.003) versus placebo with no new safety signals, positioning it as the first potential therapy for the entire HCM spectrum. The supplemental NDA for MAPLE HCM was accepted by the FDA with a PDUFA date of November 14, 2026, and management plans to pursue an additional sNDA for nHCM based on Acacia results, which could unlock a substantially larger patient population than oHCM alone. European Commission approval of MYCorzo for oHCM enables imminent German launch in Q2 2026, with six HTA dossiers already submitted across EU jurisdictions, while aficamtin's orphan drug designation in Japan for both adult nHCM and pediatric oHCM provides regulatory advantages in a key international market. The company's $1.1 billion cash balance provides ample runway to fund commercial expansion and pipeline advancement without near-term financing pressure, supporting disciplined execution of its global launch strategy for MYCorzo and progression of aficamtin toward potential approval in multiple geographies including Canada, Hong Kong, and Taiwan, where applications are pending. This combination of early commercial success, paradigm-shifting pipeline data, and strategic regulatory progress suggests the market is underestimating the durability of Cytokinetics' commercial momentum and the probability of aficamtin becoming a first-in-class therapy for nHCM, which could significantly expand its addressable market beyond the current oHCM-focused MYCorzo opportunity.
Cytokinetics has established a compelling dual-pathway growth engine through MYCorzo's successful U.S. launch and aficamtin's breakthrough Phase 3 Acacia HCM results, creating immediate revenue momentum and a near-term catalyst for expanded market opportunity. The company achieved $4.8 million in net product revenue from MYCorzo during approximately nine weeks post-launch, exceeding internal expectations for both depth and breadth of prescribing, with over 275 unique HCPs prescribing in Q1 and more than 425 by April, including strong adoption among high-volume prescribers who generate 80% of HCM prescriptions. This early traction is reinforced by over 70% of dispensed patients converting to paid prescriptions within two weeks, indicating sustainable commercial viability beyond free trial programs. Concurrently, aficamtin met both dual primary endpoints in the Acacia HCM trial for nonobstructive HCM, demonstrating a statistically significant and clinically meaningful 3-point least squares mean difference in KCCQ (p=0.021) and 0.67 mL/kg/min improvement in peak VO2 (p=0.003) versus placebo with no new safety signals, positioning it as the first potential therapy for the entire HCM spectrum. The supplemental NDA for MAPLE HCM was accepted by the FDA with a PDUFA date of November 14, 2026, and management plans to pursue an additional sNDA for nHCM based on Acacia results, which could unlock a substantially larger patient population than oHCM alone. European Commission approval of MYCorzo for oHCM enables imminent German launch in Q2 2026, with six HTA dossiers already submitted across EU jurisdictions, while aficamtin's orphan drug designation in Japan for both adult nHCM and pediatric oHCM provides regulatory advantages in a key international market. The company's $1.1 billion cash balance provides ample runway to fund commercial expansion and pipeline advancement without near-term financing pressure, supporting disciplined execution of its global launch strategy for MYCorzo and progression of aficamtin toward potential approval in multiple geographies including Canada, Hong Kong, and Taiwan, where applications are pending. This combination of early commercial success, paradigm-shifting pipeline data, and strategic regulatory progress suggests the market is underestimating the durability of Cytokinetics' commercial momentum and the probability of aficamtin becoming a first-in-class therapy for nHCM, which could significantly expand its addressable market beyond the current oHCM-focused MYCorzo opportunity.
Cytokinetics faces significant near-term commercial execution risks and pipeline uncertainty that the market may be overlooking, despite positive early launch metrics and promising clinical results for aficamtin. While MYCorzo achieved $4.8 million in net product revenue during its initial nine-week U.S. launch period, total revenue excluding MYCorzo and the Bayer milestone payment declined to $0.4 million from $1.6 million in the prior year quarter, indicating underlying weakness in legacy collaboration revenue streams that are not being adequately replaced by new product sales. The company's SG&A expenses surged to $104.9 million in Q1 2026 from $57.4 million in the same period of 2025, driven by launch-related costs and increased non-sales personnel expenses including stock-based compensation, reflecting a high fixed-cost base that must be sustained by rapid MYCorzo sales growth to achieve profitability—a challenge given that over 70% of patients were on paid prescriptions by quarter-end, but the long-term durability of this conversion rate from free trial and bridge programs remains unproven beyond the initial launch enthusiasm. Management acknowledged that the transition from free trials to paid prescriptions is expected to "repeat in future quarters" as a structural dynamic, yet provided no concrete data on retention rates or real-world adherence beyond the early adoption phase, raising concerns about whether prescriber and patient uptake can scale sustainably amid payer access barriers. Although nearly 90% of Medicare lives currently have comparable access to MYCorzo, commercial payer access is targeted at only 50% by early Q3 and full parity by year-end, creating a significant reimbursement hurdle that could limit broader adoption, especially as the company plans to shift focus from high-volume prescribers to broader prescribing only after achieving over 50% new-to-brand share among cardiologists—a milestone that may take longer than anticipated given the competitive landscape with Bristol Myers Squibb's Camzyos already established in the market. Furthermore, while aficamtin showed statistically significant improvements in KCCQ and peak VO2 in the Acacia HCM trial, the effect sizes—3-point KCCQ difference and 0.67 mL/kg/min peak VO2 gain—are modest in absolute terms and may not translate to compelling real-world outcomes that drive strong physician preference or payer coverage decisions, particularly when compared to the higher bar set by therapies in more prevalent heart failure populations. The company's reliance on a supplemental NDA pathway for aficamtin in nHCM, rather than a standalone approval, introduces regulatory timing uncertainty, and the ongoing COMET-HS trial for omecamtiv mecarbil in heart failure remains years from readout, leaving the broader pipeline vulnerable to clinical or regulatory setbacks. With cash burn of $144 million quarter-to-date and a cash balance down from $1.2 billion at 2025 year-end to $1.1 billion, the company's financial cushion, while substantial, is being depleted at a pace that could constrain flexibility if commercial execution falters or pipeline delays occur, making the current valuation potentially susceptible to downside if near-term launch momentum does not accelerate meaningfully.
Cytokinetics faces significant near-term commercial execution risks and pipeline uncertainty that the market may be overlooking, despite positive early launch metrics and promising clinical results for aficamtin. While MYCorzo achieved $4.8 million in net product revenue during its initial nine-week U.S. launch period, total revenue excluding MYCorzo and the Bayer milestone payment declined to $0.4 million from $1.6 million in the prior year quarter, indicating underlying weakness in legacy collaboration revenue streams that are not being adequately replaced by new product sales. The company's SG&A expenses surged to $104.9 million in Q1 2026 from $57.4 million in the same period of 2025, driven by launch-related costs and increased non-sales personnel expenses including stock-based compensation, reflecting a high fixed-cost base that must be sustained by rapid MYCorzo sales growth to achieve profitability—a challenge given that over 70% of patients were on paid prescriptions by quarter-end, but the long-term durability of this conversion rate from free trial and bridge programs remains unproven beyond the initial launch enthusiasm. Management acknowledged that the transition from free trials to paid prescriptions is expected to "repeat in future quarters" as a structural dynamic, yet provided no concrete data on retention rates or real-world adherence beyond the early adoption phase, raising concerns about whether prescriber and patient uptake can scale sustainably amid payer access barriers. Although nearly 90% of Medicare lives currently have comparable access to MYCorzo, commercial payer access is targeted at only 50% by early Q3 and full parity by year-end, creating a significant reimbursement hurdle that could limit broader adoption, especially as the company plans to shift focus from high-volume prescribers to broader prescribing only after achieving over 50% new-to-brand share among cardiologists—a milestone that may take longer than anticipated given the competitive landscape with Bristol Myers Squibb's Camzyos already established in the market. Furthermore, while aficamtin showed statistically significant improvements in KCCQ and peak VO2 in the Acacia HCM trial, the effect sizes—3-point KCCQ difference and 0.67 mL/kg/min peak VO2 gain—are modest in absolute terms and may not translate to compelling real-world outcomes that drive strong physician preference or payer coverage decisions, particularly when compared to the higher bar set by therapies in more prevalent heart failure populations. The company's reliance on a supplemental NDA pathway for aficamtin in nHCM, rather than a standalone approval, introduces regulatory timing uncertainty, and the ongoing COMET-HS trial for omecamtiv mecarbil in heart failure remains years from readout, leaving the broader pipeline vulnerable to clinical or regulatory setbacks. With cash burn of $144 million quarter-to-date and a cash balance down from $1.2 billion at 2025 year-end to $1.1 billion, the company's financial cushion, while substantial, is being depleted at a pace that could constrain flexibility if commercial execution falters or pipeline delays occur, making the current valuation potentially susceptible to downside if near-term launch momentum does not accelerate meaningfully.